Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study

References

• TaskinenMR, BorénJ. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239(2):483–495. doi:10.1016/j.atherosclerosis.2015.01.03925706066
   PubMed Web of Science ®Google Scholar
• MooradianAD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5(3):150–159. doi:10.1038/ncpendmet106619229235
   PubMedGoogle Scholar
• FeingoldKR Dyslipidemia in diabetes In: FeingoldKR, AnawaltB, BoyceA, et al., eds. Endotext. South Dartmouth (MA):MDText.com, Inc. Copyright © 2000–2020, MDText.com, Inc.; 2000.
   Google Scholar
• KimMK, KoSH, KimBY, et al. Clinical practice guidelines for type 2 diabetes mellitus in Korea. Diabetes Metab J. 2019;43(4):398–406. doi:10.4093/dmj.2019.013731441247
   PubMed Web of Science ®Google Scholar
• XieW, SongX, LiuZ. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases. Vascul Pharmacol. 2018;109:17–26. doi:10.1016/j.vph.2018.05.01029879463
   PubMed Web of Science ®Google Scholar
• GarberAJ, AbrahamsonMJ, BarzilayJI, et al. Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary. Endocr Pract. 2018;24(1):91–120. doi:10.4158/CS-2017-015329368965
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl1):S103–s123. doi:10.2337/dc19-S01030559236
   PubMedGoogle Scholar
• LimKS, KimJR, ChoiYJ, et al. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase iv inhibitor lc15-0444 in healthy korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study. Clin Ther. 2008;30(10):1817–1830. doi:10.1016/j.clinthera.2008.10.01319014837
   PubMed Web of Science ®Google Scholar
• KimN, PatrickL, MairS, et al. Absorption, metabolism and excretion of [14c]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Xenobiotica. 2014;44(6):522–530. doi:10.3109/00498254.2013.86585624304170
   PubMed Web of Science ®Google Scholar
• KimSH, YooJH, LeeWJ, ParkCY. Gemigliptin: an update of its clinical use in the management of type 2 diabetes mellitus. Diabetes Metab J. 2016;40(5):339–353. doi:10.4093/dmj.2016.40.5.33927766241
   PubMed Web of Science ®Google Scholar
• KangWY, SeongSJ, OhkB, et al. Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects. Drug Des Devel Ther. 2018;12:3607–3615. doi:10.2147/DDDT.S161917
   Web of Science ®Google Scholar
• Highlights of prescribing information. crestor (rosuvastatin calcium) tablets AstraZeneca pharmaceuticals LP. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021366s040s041lbl.pdf. Published 2020 Accessed 827, 2020.
   Google Scholar
• ChoiHY, LimHS, KimYH, et al. Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects. Curr Med Res Opin. 2015;31(2):229–241. doi:10.1185/03007995.2014.98088625350224
   PubMed Web of Science ®Google Scholar
• KimE, ParkKR, JangIJ, YuKS, LeeS. A fixed-dose combination of gemigliptin and rosuvastatin exhibits similar pharmacokinetics, pharmacodynamics, and safety compared to that of a loose combination in healthy subjects. Drug Des Devel Ther. 2019;13:3879–3885. doi:10.2147/DDDT.S197054
   PubMed Web of Science ®Google Scholar
• DesaiD, WangJ, WenH, LiX, TimminsP. Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharm Dev Technol. 2013;18(6):1265–1276. doi:10.3109/10837450.2012.66069922339230
   PubMed Web of Science ®Google Scholar
• ThotaS, TippabhotlaSK, KhanS, NakkawarM. Two-way crossover bioequivalence study of rosuvastatin tablets 5 mg in healthy, adult, asian-indian male volunteers under fasting condition. Int J Pharm Pharm Sci. 2013;5(3):289–293.
   Google Scholar
• Han S. Analysis of Gemigliptin and LC15-0636 in Human Plasma by LC-MS/MS (Study No.: AN1-18-116). International Scientific Standards, Inc. 2019
   Google Scholar
• Park J. Sample Analytical Report (Quantitative analysis of Rosuvastatin in human plasma by LC/MS/MS), (Clinical Study Title: a randomized, open-label, single dose, two-way crossover clinical trial to investigate the pharmacokinetics/pharmacodynamics, safety, and tolerability of the monolayer combination of gemigliptin/rosuvastatin 50/20 mg in comparison to the bilayer combination of gemigliptin/rosuvastatin 50/20 mg administered in healthy volunteers, Study No.: DDS19-643AN_R (Ver.01). BioCore Co., Ltd. 2019
   Google Scholar
• ShinD, ChoYM, LeeS, et al. Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects. Clin Drug Investig. 2014;34(6):383–393. doi:10.1007/s40261-014-0184-3
   PubMed Web of Science ®Google Scholar
• NohYH, LimHS, JinSJ, et al. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-iv inhibitor: a crossover drug-drug interaction study in healthy male korean volunteers. Clin Ther. 2012;34(5):1182–1194. doi:10.1016/j.clinthera.2012.04.00122534255
   PubMed Web of Science ®Google Scholar
• Guidance for Industry. Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an anda. U.S. Food and Drug Administration https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioequivalence-studies-pharmacokinetic-endpoints-drugs-submitted-under-abbreviated-new-drug. Published 2013 Accessed 827, 2020.
   Google Scholar
• ParkSI, LeeH, OhJ, et al. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects. Drug Des Devel Ther. 2015;9:729–736. doi:10.2147/DDDT.S75980
   Web of Science ®Google Scholar
• JinX, KimE, HuhKY, et al. Pharmacokinetics and pharmacodynamics of a fixed-dose combination of gemigliptin/metformin sustained release 25/500 mg compared to the loose combination in healthy male subjects. Transl Clin Pharmacol. 2020;28(1):43–54. doi:10.12793/tcp.2020.28.e232274380
   PubMedGoogle Scholar
• PathakR, BridgemanMB. Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes. P T. 2010;35(9):509–513.20975810
   PubMedGoogle Scholar